These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2918 related articles for article (PubMed ID: 10750516)

  • 1. Tuberculosis chemotherapy and sputum conversion among HIV-seropositive and HIV-seronegative patients in south-eastern Uganda.
    Bwire R; Borgdorff MW; Sticht-Groh V; Rieder HL; Kawuma HJ; Bretzel G; Rüsch-Gerdes S
    East Afr Med J; 1999 Jun; 76(6):307-13. PubMed ID: 10750516
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors influencing time to smear conversion in patients with smear-positive pulmonary tuberculosis.
    Wang JY; Lee LN; Yu CJ; Chien YJ; Yang PC;
    Respirology; 2009 Sep; 14(7):1012-9. PubMed ID: 19659516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
    Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H
    Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of human immunodeficiency virus on response to treatment and recurrence rate in patients treated for tuberculosis: two-year follow-up of a cohort in Lusaka, Zambia.
    Elliott AM; Halwiindi B; Hayes RJ; Luo N; Mwinga AG; Tembo G; Machiels L; Steenbergen G; Pobee JO; Nunn PP
    J Trop Med Hyg; 1995 Feb; 98(1):9-21. PubMed ID: 7861484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Should we take a history of prior treatment, and check sputum status at 2-3 months when treating patients for tuberculosis?
    Wilkinson D; Bechan S; Connolly C; Standing E; Short GM
    Int J Tuberc Lung Dis; 1998 Jan; 2(1):52-5. PubMed ID: 9562111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long term follow up of HIV-infected patients with tuberculosis treated with 6-month intermittent short course chemotherapy.
    Swaminathan S; Deivanayagam CN; Rajasekaran S; Venkatesan P; Padmapriyadarsini C; Menon PA; Ponnuraja C; Dilip M
    Natl Med J India; 2008; 21(1):3-8. PubMed ID: 18472696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical aspects and treatment outcome in HIV-associated pulmonary tuberculosis: an experience from a Thai referral centre.
    Hongthiamthong P; Riantawan P; Subhannachart P; Fuangtong P
    J Med Assoc Thai; 1994 Oct; 77(10):520-5. PubMed ID: 7745373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The bacteriology of pulmonary tuberculosis in a population with high human immunodeficiency virus seroprevalence.
    Karstaedt AS; Jones N; Khoosal M; Crewe-Brown HH
    Int J Tuberc Lung Dis; 1998 Apr; 2(4):312-6. PubMed ID: 9559402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determination of drug susceptibility and DNA fingerprint patterns of clinical isolates of Mycobacterium tuberculosis from Kampala, Uganda.
    Joloba ML; Whalen CC; Cave DM; Eisenach KD; Johnson JL; Okwera A; Morrissey A; Bajaksouzian S; Feagin J; Mugerwa R; Ellner J; Jacobs MR
    East Afr Med J; 2000 Feb; 77(2):111-5. PubMed ID: 10774085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modified short-course chemotherapy of pulmonary tuberculosis in Ibadan, Nigeria--a preliminary report.
    Ige OM; Bakare NA; Onadeko BO
    Afr J Med Med Sci; 2000 Mar; 29(1):51-3. PubMed ID: 11379469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [In 76% of patients with active tuberculosis treated with triple therapy (isoniazid-rifampicin-pyrazinamide) cultural conversion precedes microscopic conversion].
    Nowak D; Radenbach D; Magnussen H
    Pneumologie; 1990 Feb; 44 Suppl 1():497-8. PubMed ID: 2114634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk factors for negative sputum acid-fast bacilli smears in pulmonary tuberculosis: results from Dakar, Senegal, a city with low HIV seroprevalence.
    Samb B; Sow PS; Kony S; Maynart-Badiane M; Diouf G; Cissokho S; Bâ D; Sané M; Klotz F; Faye-Niang MA; Mboup S; Ndoye I; Delaporte E; Hane AA; Samb A; Coulaud JP; Coll-Seck AM; Larouzé B; Murray JF
    Int J Tuberc Lung Dis; 1999 Apr; 3(4):330-6. PubMed ID: 10206504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
    API Consensus Expert Committee
    J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of anti-tuberculosis drug resistance on the treatment outcome of pulmonary tuberculosis patients receiving DOTS in Riyadh, Saudi Arabia.
    Singla R; Al-Sharif N; Al-Sayegh MO; Osman MM; Shaikh MA
    Int J Tuberc Lung Dis; 2002 Jul; 6(7):585-91. PubMed ID: 12102297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Critical assessment of smear-positive pulmonary tuberculosis patients after chemotherapy under the district tuberculosis programme.
    Datta M; Radhamani MP; Selvaraj R; Paramasivan CN; Gopalan BN; Sudeendra CR; Prabhakar R
    Tuber Lung Dis; 1993 Jun; 74(3):180-6. PubMed ID: 8369512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rifapentine and isoniazid in the continuation phase of a 6-month regimen. Final report at 5 years: prognostic value of various measures.
    Tam CM; Chan SL; Kam KM; Goodall RL; Mitchison DA
    Int J Tuberc Lung Dis; 2002 Jan; 6(1):3-10. PubMed ID: 11931398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV seroprevalence rate and incidence of adverse skin reactions in adults with pulmonary tuberculosis receiving thiacetazone free anti-tuberculosis treatment in Yaounde, Cameroon.
    Kuaban C; Bercion R; Koulla-Shiro S
    East Afr Med J; 1997 Aug; 74(8):474-7. PubMed ID: 9487410
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Results of a therapeutic trial comparing a 6-month regimen to a 12-month regimen in the treatment of pulmonary tuberculosis in the Algerian Sahara. Final report: results 3 years after the onset of treatment].
    Berkani M; Chaulet P; Darbyshire JH; Nunn A; Fox W
    Rev Mal Respir; 1986; 3(2):73-85. PubMed ID: 3726263
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current HIV seroprevalence rate and incidence of adverse skin reactions in adults with pulmonary tuberculosis receiving thiacetazone-free antituberculosis treatment in Yaounde, Cameroon.
    Kuaban C; Bercion R; Koula-Shiro S
    Cent Afr J Med; 1998 Feb; 44(2):34-7. PubMed ID: 9675969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A controlled study of rifabutin and an uncontrolled study of ofloxacin in the retreatment of patients with pulmonary tuberculosis resistant to isoniazid, streptomycin and rifampicin. Hong Kong Chest Service/British Medical Research Council.
    Tuber Lung Dis; 1992 Feb; 73(1):59-67. PubMed ID: 1326349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 146.